ArticleFrontiers in oncology2025
The value of multi-sequence magnetic resonance imaging and whole-tumor apparent diffusion coefficient histogram analysis in differentiating p53 abnormal from non-p53 abnormal endometrial carcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Role of apparent diffusion coefficient (ADC) and MRI-derived parameters in identifying p53-abnormal subtypes of endometrial cancer.European journal of radiology open · 2026Article
- Comparing multi-b-value diffusion models and ROI delineation strategies for prediction of p53 abnormality and microsatellite instability in endometrial cancer.BMC medical imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the utility of multi-sequence magnetic resonance imaging (MRI) and whole-tumor apparent diffusion coefficient (ADC) histogram metrics in preoperatively differentiating p53 abnormal (p53abn) from non-p53abn endometrial carcinoma (EC). Methods: This retrospective study included 146 EC patients (29 p53abn cases and 117 non-p53abn cases) who underwent preoperative MRI scans. MRI features were analyzed. Whole-tumor ADC histogram analysis was conducted by delineating regions of interest (ROIs) on diffusion-weighted imaging (DWI) scans. Receiver operating characteristic (ROC) curve analysis with the area under the curve (AUC) was used for diagnostic performance evaluation. Results: Extrauterine extension (p=0.004) and lymphadenopathy (p=0.005) were more frequently observed in p53abn EC compared to non-p53abn EC. p53abn EC exhibited significantly lower value of minADC (p=0.001), meanADC (p=0.005), P10 (p=0.009), P50 (p=0.007), and P90 (p=0.013) ADC and higher value of kurtosis (p=0.008), compared to non-p53abn EC. MinADC demonstrated the highest discrimination ability in differentiating p53abn from non-p53abn EC [AUC 0.70(0.60;0.80)]. Conclusion: Preoperative multi-sequence MRI findings and whole-tumor ADC histogram metrics are conducive to differentiating p53abn from non-p53abn EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.